论文部分内容阅读
目的研究肝脏炎性疾病患者血浆中组织因子途径抑制物（ＴＦＰＩ）与抗凝血酶Ⅲ（ＡＴ－Ⅲ）的改变及其临床意义。方法ＴＦＰＩ抗原（ＴＦＰＩ：Ａｇ）采用双夹心ＥＬＩＳＡ抗原测定法，ＴＦＰＩ活性（ＴＦＰＩ：Ａ）采用发色底物法，ＡＴ－Ⅲ：Ａｇ采用免疫浊度法，ＡＴ－Ⅲ：Ａ采用发色底物法。结果急性中毒性肝炎１４例，急性病毒性肝炎２０例，慢性乙型肝炎４８例，共８２例肝脏炎性疾病患者ＴＦＰＩ：Ａｇ与ＴＦＰＩ：Ａ均高于正常值（Ｐ＜０．０５，Ｐ＜０．０１），ＡＴ－Ⅲ：Ａｇ均接近正常值，ＡＴ－Ⅲ：Ａ除慢性乙肝中度低于正常值外，其余接近正常值。结论肝脏炎性疾病ＴＦＰＩ均上调，表明组织受损，炎症存在。而ＡＴ－Ⅲ可正常或降低，表明肝细胞分泌ＡＴ－Ⅲ有一定程度减少。
Objective To study the changes of plasma Tissue factor pathway inhibitor (TFPI) and antithrombin Ⅲ (AT-Ⅲ) in patients with inflammatory diseases of the liver and its clinical significance. Methods TFPI antigen (TFPI: Ag) was detected by double sandwich ELISA. TFPI activity (TFPI: A) was determined by chromogenic substrate method. AT- Material law. Results TFPI: Ag and TFPI: A were significantly higher than the normal values in 14 cases of acute toxic hepatitis, 20 cases of acute viral hepatitis and 48 cases of chronic hepatitis B in 82 cases of liver inflammatory diseases (P <0.05, P <0.01), AT-Ⅲ: Ag are close to normal, AT-Ⅲ: A except chronic hepatitis B moderate lower than normal, the rest close to normal. Conclusions TFPI in liver inflammatory diseases are up-regulated, indicating that the tissue is damaged and inflammation exists. The AT-Ⅲ can be normal or decreased, indicating that the secretion of AT-Ⅲ hepatocytes to a certain extent reduce.